MISX:ISKJ

Stock Analysis Report

Human Stem Cells Institute PJSC

Executive Summary

Human Stem Cells Institute PJSC operates as a biotech company primarily in Russia.

Rewards

PE ratio (15.9x) is below the Biotechs industry average (35.3x)

Became profitable this year

Risk Analysis

Debt is not well covered by operating cash flow

Does not have a meaningful market cap (RUB938M)



Snowflake Analysis

Acceptable track record with imperfect balance sheet.

Share Price & News

How has Human Stem Cells Institute PJSC's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ISKJ has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.4%

ISKJ

1.2%

RU Biotechs

2.3%

RU Market


1 Year Return

71.1%

ISKJ

30.0%

RU Biotechs

28.8%

RU Market

Return vs Industry: ISKJ exceeded the Russian Biotechs industry which returned 27.3% over the past year.

Return vs Market: ISKJ exceeded the Russian Market which returned 28.5% over the past year.


Shareholder returns

ISKJIndustryMarket
7 Day4.4%1.2%2.3%
30 Day1.6%4.9%6.9%
90 Day9.8%21.4%14.5%
1 Year71.1%71.1%30.7%30.0%37.8%28.8%
3 Year-23.8%-23.8%39.9%37.2%67.2%40.7%
5 Year32.1%30.2%80.1%75.7%161.2%103.0%

Price Volatility Vs. Market

How volatile is Human Stem Cells Institute PJSC's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Human Stem Cells Institute PJSC undervalued compared to its fair value and its price relative to the market?

16.66x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ISKJ's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ISKJ's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ISKJ is good value based on its PE Ratio (15.9x) compared to the Biotechs industry average (35.3x).

PE vs Market: ISKJ is poor value based on its PE Ratio (15.9x) compared to the Russian market (8.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ISKJ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ISKJ is overvalued based on its PB Ratio (6.4x) compared to the XE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Human Stem Cells Institute PJSC forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

19.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Human Stem Cells Institute PJSC has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Human Stem Cells Institute PJSC performed over the past 5 years?

0.02%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ISKJ has high quality earnings.

Growing Profit Margin: ISKJ became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ISKJ has become profitable over the past 5 years, growing earnings by 0.02% per year.

Accelerating Growth: ISKJ has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ISKJ has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: Whilst ISKJ's Return on Equity (34.26%) is high, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Human Stem Cells Institute PJSC's financial position?


Financial Position Analysis

Short Term Liabilities: ISKJ's short term assets (RUB501.9M) exceed its short term liabilities (RUB411.1M).

Long Term Liabilities: ISKJ's short term assets (RUB501.9M) do not cover its long term liabilities (RUB756.6M).


Debt to Equity History and Analysis

Debt Level: ISKJ's debt to equity ratio (146.3%) is considered high.

Reducing Debt: ISKJ's debt to equity ratio has increased from 29.1% to 146.3% over the past 5 years.

Debt Coverage: ISKJ's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: ISKJ's interest payments on its debt are well covered by EBIT (5.9x coverage).


Balance Sheet

Inventory Level: ISKJ has a high level of physical assets or inventory.

Debt Coverage by Assets: ISKJ's debt is covered by short term assets (assets are 1.3x debt).


Next Steps

Dividend

What is Human Stem Cells Institute PJSC's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%3.3%markettop25%7.9%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ISKJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ISKJ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ISKJ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ISKJ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: ISKJ is not paying a notable dividend for the Russian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ISKJ's dividend in 3 years as they are not forecast to pay a notable one for the Russian market.


Next Steps

Management

What is the CEO of Human Stem Cells Institute PJSC's salary, the management and board of directors tenure and is there insider trading?


CEO

Artur Isaev (49yo)

0yrs

Tenure

0

Dr. Artur Aleksandrovich Isaev, M.D., has been a General Director of Human Stem Cells Institute PJSC since 2003. Since 1999, Dr. Isaev serves as Vice President of the Russian Association of Regenerative Me ...


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Artur Isaev (49yo)

    General Director

    • Nadezhda Aliutova

      Chief Accountant

      • Alexander Prikhodko (60yo)

        Chairman

        • Tenure: 7.5yrs
      • Roman Deev

        Chief Scientific Officer

        • Vadim Zorin

          Head of Regenerative Medicine Department & Member of Scientific Advisory Board

          • Svetlana Samoylova

            Director of Investor Relations & IBD and Member of Audit Commission

            • Natalia Dereviannyh

              Human Resources Director

              • Olga Sidorova

                Chief Financial Officer

                • Tatiana Tiutiunnikova

                  Administrative Director

                  • Igor Chernykh

                    Managing Director


                    Board Members

                    • Artur Isaev (49yo)

                      General Director

                      • Alexander Prikhodko (60yo)

                        Chairman

                        • Tenure: 7.5yrs
                      • Roman Deev

                        Chief Scientific Officer

                        • Sergey Kiselev (61yo)

                          Independent Director & Member of Scientific Advisory Board

                          • Ivan Potapov

                            Member of Scientific Advisory Board

                            • Vadim Zorin

                              Head of Regenerative Medicine Department & Member of Scientific Advisory Board

                              • Dmitry Alexandrov (38yo)

                                Independent Director

                                • Svetlana Samoylova

                                  Director of Investor Relations & IBD and Member of Audit Commission

                                  • Svetlana Blokhina

                                    Financial Control & Internal Audit Officer and Chairman of Audit Commission

                                    • Oksana Peterson

                                      Deputy Chief Accountant & Member of Audit Commission

                                      Company Information

                                      Human Stem Cells Institute PJSC's company bio, employee growth, exchange listings and data sources


                                      Key Information

                                      • Name: Human Stem Cells Institute PJSC
                                      • Ticker: ISKJ
                                      • Exchange: MISX
                                      • Founded: 2003
                                      • Industry: Biotechnology
                                      • Sector: Pharmaceuticals & Biotech
                                      • Market Cap: ₽984.155m
                                      • Shares outstanding: 71.99m
                                      • Website: https://www.hsci.ru

                                      Location

                                      • Human Stem Cells Institute PJSC
                                      • 18/1 Olimpiysky prospect
                                      • Moscow
                                      • 129110
                                      • Russia

                                      Listings

                                      TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
                                      ISKJMISX (Micex - Rts)YesOrdinary SharesRURUBFeb 2010

                                      Biography

                                      Human Stem Cells Institute PJSC operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation. The company also offers Neovasculgen, a gene-therapy drug for treatment of peripheral arterial disease, including critical limb ischemia; and SPRS-therapy (service for personal regeneration of skin), a set of personalized diagnostics and treatment procedures for repairing skin damages. In addition, it operates GENETICO, a medical genetics center and molecular diagnostic lab that provides a range of genetic analysis and counseling services for the early detection, prediction, and prophylactic treatment of genetic disorders, including reproductive system diseases; and provides preimplantation genetic diagnosis and screening that includes testing of developing embryos for monogenic inherited diseases and chromosome abnormalities during an in vitro fertilization cycle. Further, the company offers non-invasive prenatal testing of fetal chromosome abnormalities; and develops Gemacell, a cell-based drug candidate for treatment of myocardial infarction. Additionally, it provides range of diagnostic services for identification of genetic predisposition to oncological diseases; and distributes cell processing equipment. Human Stem Cells Institute PJSC was founded in 2003 and is based in Moscow, Russia. Human Stem Cells Institute PJSC operates as a subsidiary of Mezhdunarodnogo Meditsinskogo Centra Obrabotki i Kriokhraneniya Biomaterialy.  


                                      Company Analysis and Financial Data Status

                                      All financial data provided by Standard & Poor's Capital IQ.
                                      DataLast Updated (UTC time)
                                      Company Analysis2020/01/17 21:17
                                      End of Day Share Price2020/01/17 00:00
                                      Earnings2019/06/30
                                      Annual Earnings2018/12/31


                                      Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.